The mechanisms underlying the resistance pathways to adjuvant aromatase inhibitors in HR+ breast cancer remain unclear, and are likely to be multifactorial, involving a combination of both tumor and host factors. The gene discussed is CYP19A1; the disease is breast carcinoma.